Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Downregulation and prognostic performance of microRNA 224 expression in prostate cancer.

Mavridis K, Stravodimos K, Scorilas A.

Clin Chem. 2013 Jan;59(1):261-9. doi: 10.1373/clinchem.2012.191502. Epub 2012 Nov 7.

2.

MicroRNA expression profiles in the progression of prostate cancer--from high-grade prostate intraepithelial neoplasia to metastasis.

Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sañudo A, Camara-Lopes LH, Srougi M.

Urol Oncol. 2013 Aug;31(6):796-801. doi: 10.1016/j.urolonc.2011.07.002. Epub 2011 Aug 30.

PMID:
21880514
3.

Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.

Gonzales JC, Fink LM, Goodman OB Jr, Symanowski JT, Vogelzang NJ, Ward DC.

Clin Genitourin Cancer. 2011 Sep;9(1):39-45. doi: 10.1016/j.clgc.2011.05.008. Epub 2011 Jul 1.

PMID:
21723797
4.

Do microRNA 96, 145 and 221 expressions really aid in the prognosis of prostate carcinoma?

Kang SG, Ha YR, Kim SJ, Kang SH, Park HS, Lee JG, Cheon J, Kim CH.

Asian J Androl. 2012 Sep;14(5):752-7. doi: 10.1038/aja.2012.68. Epub 2012 Aug 6.

5.

Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer.

Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, Kantoff PW.

Prostate. 2013 Mar;73(4):346-54. doi: 10.1002/pros.22572. Epub 2012 Aug 10.

6.

MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma.

Lin RJ, Xiao DW, Liao LD, Chen T, Xie ZF, Huang WZ, Wang WS, Jiang TF, Wu BL, Li EM, Xu LY.

J Surg Oncol. 2012 Feb;105(2):175-82. doi: 10.1002/jso.22066. Epub 2011 Aug 22.

PMID:
21882196
7.

Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy.

Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masiá E, Casanova J, Fernández-Serra A, Rubio L, Ramírez-Backhaus M, Armiñán A, Domínguez-Escrig J, Martínez F, García-Casado Z, Scotlandi K, Vicent MJ, López-Guerrero JA.

J Urol. 2014 Jul;192(1):252-9. doi: 10.1016/j.juro.2014.01.107. Epub 2014 Feb 8.

PMID:
24518785
8.

Importance of miR-20a expression in prostate cancer tissue.

Pesta M, Klecka J, Kulda V, Topolcan O, Hora M, Eret V, Ludvikova M, Babjuk M, Novak K, Stolz J, Holubec L.

Anticancer Res. 2010 Sep;30(9):3579-83.

PMID:
20944140
10.

Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance.

Avgeris M, Stravodimos K, Scorilas A.

Prostate. 2011 Dec;71(16):1780-9. doi: 10.1002/pros.21395. Epub 2011 Apr 25.

PMID:
21520157
11.

Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.

Li T, Gui Y, Yuan T, Liao G, Bian C, Jiang Q, Huang S, Liu B, Wu D.

BJU Int. 2012 Dec;110(11 Pt C):E1125-30. doi: 10.1111/j.1464-410X.2012.11277.x. Epub 2012 Jun 6.

12.

Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis.

Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y.

Biomed Pharmacother. 2010 Jul;64(6):399-408. doi: 10.1016/j.biopha.2010.01.018. Epub 2010 Feb 25.

PMID:
20363096
13.

MicroRNA detection in prostate tumors by quantitative real-time PCR (qPCR).

Gordanpour A, Nam RK, Sugar L, Bacopulos S, Seth A.

J Vis Exp. 2012 May 16;(63):e3874. doi: 10.3791/3874.

14.

Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer.

Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, Qu W, Nair S, Horvath LG, Armstrong NJ, Kench JG, Sutherland RL, Clark SJ.

Oncogene. 2013 Jun 6;32(23):2891-9. doi: 10.1038/onc.2012.300. Epub 2012 Aug 6.

PMID:
22869146
15.

miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression.

Fendler A, Jung M, Stephan C, Honey RJ, Stewart RJ, Pace KT, Erbersdobler A, Samaan S, Jung K, Yousef GM.

Int J Oncol. 2011 Nov;39(5):1183-92. doi: 10.3892/ijo.2011.1128. Epub 2011 Jul 18.

PMID:
21769427
16.

Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma.

Chang C, Shi H, Wang C, Wang J, Geng N, Jiang X, Wang X.

Neurosci Lett. 2012 Dec 7;531(2):204-8. doi: 10.1016/j.neulet.2012.10.021. Epub 2012 Oct 26.

PMID:
23103713
17.
18.

Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.

Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H.

Mod Pathol. 2012 Jan;25(1):112-21. doi: 10.1038/modpathol.2011.142. Epub 2011 Oct 7.

19.

Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis.

Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sañudo A, Antunes AA, Srougi M.

Urol Oncol. 2011 May-Jun;29(3):265-9. doi: 10.1016/j.urolonc.2009.02.002. Epub 2009 Apr 16.

PMID:
19372056
20.

Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer.

Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R.

Oncol Rep. 2012 Jun;27(6):1759-64. doi: 10.3892/or.2012.1709. Epub 2012 Mar 7.

PMID:
22407237

Supplemental Content

Support Center